Please ensure Javascript is enabled for purposes of website accessibility

2 Dirt-Cheap Robinhood Stocks That Could Skyrocket

By Will Ebiefung – Updated Aug 24, 2020 at 8:39AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

These cheap companies have upcoming binary catalysts for explosive growth.

High risk comes with high potential rewards, and some stocks take this a step further by staking their entire business model on a single catalyst for growth. These stocks can make good investments, because their potential gains vastly outweigh potential losses (which are capped at 100%). 

Here are two dirt cheap Robinhood stocks poised to deliver multi-bagger returns if they successfully execute on their long-term growth drivers. The first pick is Corbus Pharmaceuticals (CRBP -5.61%), a small-cap biotech betting everything on its cannabinoid drug lenabasum. The second pick is Virgin Galactic (SPCE -3.29%), a mid-cap space tourism company with the potential for rocketship returns. Both companies have market caps below $5 billion, and enjoy binary (yes or no) catalysts for explosive growth. 

Paper rocket made out of dollar bills

Image Source: Getty Images.

1. Corbus Pharmaceuticals 

 Corbus Pharmaceuticals is a late-stage biotech company with an exciting all or nothing business model. 

The company is working on a drug called lenabasum, which targets the endocannabinoid system to fight autoimmune diseases like systemic sclerosis, dermatomyositis, and lupus erythematosus. All three indications have successfully passed Phase 1 testing, and the drug is on schedule for Phase 3 data for systemic sclerosis this summer, with a projected launch in 2021.

If lenabasum wins regulatory approval, Corbus Pharmaceuticals stock could skyrocket significantly higher than its current $630 million market cap. According to Jefferies, systemic sclerosis has 200,000 patients in the U.S., E.U, and Japan, representing a $1.4 billion- $2.2 billion potential market opportunity for the drug in this indication alone.

That's not even including lenabasum's other indications like dermatomyositis and cystic fibrosis, which could potentially generate $0.7-$3 billion in combined annual revenue.

While Corbus Pharmaceuticals has a preclinical library of over 700 drug candidates, the company looks like an all-or-nothing bet on lenabasum. That's because the biotech's relatively small cash position ($63.5 million as of the second quarter) may not be enough to bring its other drugs to market without significant equity dilution for investors.

2. Virgin Galactic 

Virgin Galactic is another cheap Robinhood stock that could potentially skyrocket (literally). Trading at $17.53 at the time of writing, this space tourism company's relatively small $4.1 billion market cap could become significantly bigger if it successfully sends passengers to space.

Virgin Galactic's key growth catalyst will be the launch of its maiden voyage with passengers. But before taking this step, the company is shoring up its balance sheet with cash, and conducting a series of tests to establish the safety and viability of its space mission.

Most recently, Virgin Galactic closed a public offering of 23.6 million shares of common stock at $19.50 per share, a deal that netted the company $460.2 million. While dilutive equity raises can be discouraging for some investors, this is the right move because it buys Virgin Galactic more runway to safely execute its strategy. The new cash boosts the company's already strong balance sheet, which stood at $359.9 million as of second quarter earnings report on August 3.

Virgin Galactic completed eight test flights in the second quarter, and has cleared 27 of 29 verification and validation elements required by the FAA to conduct spaceflight missions. The company has also registered 600 potential paying customers and plans to send its first passengers to space in 2021.

Will Ebiefung has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Virgin Galactic Holdings Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Corbus Pharmaceuticals Holdings, Inc. Stock Quote
Corbus Pharmaceuticals Holdings, Inc.
CRBP
$0.17 (-5.61%) $0.01
Virgin Galactic Holdings, Inc. Stock Quote
Virgin Galactic Holdings, Inc.
SPCE
$4.71 (-3.29%) $0.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.